The AtheroGene Study
The objective of the AtheroGene study is to assess the value of clinical and molecular biomarkers for secondary prevention in patients with coronary artery disease.
Overview
- Acronym
- AtheroGene
- Investigators
-
- Contacts
-
General Design
- Study design
- Cohort
- Start - End Year
- 1996 - 2010
- General Information on Follow Up (profile, frequency)
-
The mean follow-up time was 4.7 years (maximum 5.4 years). Participants were followed-up for causes of death and clinical events. Follow-up information was obtained from hospital and general-practitioner charts.
- Recruitment Target
-
- Individuals
- Number of Participants
- 3,800
- Number of Participants with Biological Samples
- 3,800
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
- By contacting the study representative: Dr. Tanja Zeller (University Medical Center Hamburg Eppendorf)
Sector of research
| Possible Access to Data | Possible Access to Biosamples | |
| Investigators from the public sector | ||
| Investigators from the private sector | ||
| Investigators from not-for-profit organization |
Transfer
| Possible Access to Data | Possible Access to Biosamples | |
| Can leave the study facility | ||
| Can leave the country |
Cost
| Possible Access to Data | Variable Cost |
| Possible Access to Biosamples | Variable Cost |
Cost reduction for co-analyses
| Possible Access to Data | |
| Possible Access to Biosamples |
Access only upon submission of project-specific proposal and approval by Access committee of the study. Study specific contract is needed.
Marker Paper
Blankenberg S, Rupprecht HJ, Bickel C, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. New England Journal of Medicine, 2003; 349(17), 1605–1613.
PUBMED 14573732Timeline
Population
AtheroGene population
The population was composed of catheter-lab based patients with known coronary artery disease (at least one stenosis over 30%) in a major coronary artery as diagnosed by coronary angiography.
Selection Criteria
- Countries
-
- Germany
- Territory
- Mainz and Koblenz
- Health Status
-
- Inclusion:
- Prevalent coronary artery disease with angiographical diagnosis.
- Exclusions:
- Evidence of hemodynamically significant valvular heart disease, surgery or trauma within the previous month, known cardiomyopathy, known cancer, febrile conditions, or use of oral anticoagulant therapy within the previous 4 weeks.
Sources of Recruitment
- Specific Population
-
- Other specific population : Patients with documented coronary artery disease
- Supplementary Information
-
CAD was diagnosed if the coronary angiogram showed at least one stenosis >30% in a major coronary artery. Unstable angina was diagnosed according to Braunwald.. Acute myocardial infarction (AMI) was either ST-segment elevation with significant elevation in at least two contiguous leads or non-ST-elevation myocardial infarction based on clinic and positive in-house troponin concentrations. The final diagnosis of ACS (UA, NSTEMI, or STEMI) was made retrospectively based on the judgment of two physicians, with access to the history and nature of the presenting symptoms, medical history, results of physical examination.
Sample Size
- Number of Participants
- 3,800
- Number of Participants with Biological Samples
- 3,800
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | AtheroGene - Recruitment |
|
|
1996 (June) | 2004 (January) |
| 1 | AtheroGene - Follow-up |
|
1998 (June) | 2010 (March) |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2023-08-10T18:18:21.837